Companies: 10,795·Total market cap: $144.5T
Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc.

FHTXNASDAQHealthcare● Active
$3.64
$-0.09(-2.43%)
Market Cap$213677496
P/E Ratio—
52W High$6.95
52W Low$3.27
SEC Filings

Foghorn Therapeutics Inc. (FHTX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001822462 · FHTX · NASDAQ · as of Jun 8, 2026

Filing snapshot

339
Total Filings
SCHEDULE 13G/A
Latest Form
2026-05-15
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001822462 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-11
Fiscal Year End
Mar 11, 2026
Accession No.
0001628280-26-016814
Primary Document
fhtx-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001822462 · Accession 0001628280-26-016814

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-07Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-14
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-06
View
ARSARS
ARS
2026-04-30
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-30
View
DEF 14AProxy Statement
DEF 14A
2026-04-30
View
8-KCurrent Report
8-K
2026-04-21
View
S-8Employee Stock Plan Registration
S-8
2026-03-26
View
10-KAnnual Report
10-K
2026-03-11
View
8-KCurrent Report
8-K
2026-03-11
View
3Initial Statement of Beneficial Ownership
PRIMARY DOCUMENT
2026-02-24
View
8-KCurrent Report
8-K
2026-02-23
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-01-13
View
Showing 1–15 of 220 filingsForm 4 / 144 hidden· 339 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001822462  |  Exchange: NASDAQ · Healthcare

Foghorn Therapeutics Inc. (NASDAQ: FHTX) has submitted 339 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001822462, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Foghorn Therapeutics Inc.'s most comprehensive regulatory disclosure. The most recent Foghorn Therapeutics Inc. 10-K was filed on 2026-03-11 for fiscal year ending 2026. Historical FHTX 10-K annual reports are available from 2020 through 2026.

Investors researching Foghorn Therapeutics Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
VNDA SEC Filings →ASMB SEC Filings →ENTA SEC Filings →TRDA SEC Filings →HUMA SEC Filings →ZURA SEC Filings →SGMT SEC Filings →ARCT SEC Filings →
→ FHTX Financials→ FHTX Earnings→ FHTX Insider Trades

Frequently Asked Questions

FHTX SEC Filings · 8 questions

Foghorn Therapeutics Inc. (FHTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 339 filings and access original documents at no cost. Foghorn Therapeutics Inc.'s CIK is 0001822462.

FHTX SEC filingsFoghorn Therapeutics Inc. SEC documentsfind FHTX 10-K